Why ribonucleases induce tumor cell death

Molecular Biology

Volumn 39, Issue 1, 2005, Pages 1-10

  Ilinskaya, O N ^a   Makarov, A A ^b  

^a KAZAN FEDERAL UNIVERSITY   (Russian Federation)

^b ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

Author keywords

Antitumor activity; Catalytic activity; Charge; Cytotoxicity; KCa channels; Ras; Ribonucleases; RNA interference; Stability; Structure

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CYANAMIDE; CYTOTOXIC AGENT; DIGITONIN; DOUBLE STRANDED RNA; DOXORUBICIN; ETHYLENEDIAMINE; GLYCINE METHYL ESTER; HYALURONIDASE; HYBRID PROTEIN; INTERLEUKIN 2; IODINE 125; LECTIN; MACROGOL; MESSENGER RNA; MICRORNA; PANCREATIC RIBONUCLEASE; PROTEIN INHIBITOR; RANPIRNASE; RAS PROTEIN; RECEPTOR PROTEIN; RIBONUCLEASE; RIBONUCLEASE A; RIBONUCLEASE III; SIALIC ACID; TAURINE;

ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; CALCIUM ACTIVATED POTASSIUM CHANNEL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL DAMAGE; CELL INTERACTION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMPARATIVE STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STABILITY; DRUG STRUCTURE; DRUG TARGETING; ENDOSOME; ENZYME MECHANISM; EXPERIMENTAL MOUSE; GENE EXPRESSION; GENE FUNCTION; GENETIC ENGINEERING; HELA CELL; HUMAN; HYDROLYSIS; HYDROPHILICITY; HYDROPHOBICITY; IMMUNOFLUORESCENCE; IN VIVO STUDY; LEUKEMIA CELL; MELANOMA; MUTATION; MUTATIONAL ANALYSIS; NASOPHARYNX CARCINOMA; NEUROBLASTOMA; NEUROPATHOLOGY; NONHUMAN; NUDE MOUSE; ONCOGENE C MYC; ONCOGENE RAS; PHARMACODYNAMICS; PROTEIN DEGRADATION; PROTEIN PROCESSING; PROTO ONCOGENE; REVIEW; RNA CLEAVAGE; RNA INTERFERENCE; RNA METABOLISM; STRUCTURE ACTIVITY RELATION; TUMOR CELL; TUMOR CELL DESTRUCTION;

EID: 21744445959     PISSN: 00268933     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11008-005-0001-4     Document Type: Review

References (76)

1. Deutscher M.P., Li Z. 2001. Exoribonucleases and their multiple roles in RNA metabolism. Prog. Nucleic Acid Res. Mol. Biol. 66, 67-105.
2. Harder J., Schroder J.M. 2002. RNase 7, a novel innate immune defense antimicrobial protein of healthy human skin. J. Biol. Chem. 277, 46784-16799.
3. Rosenberg H.F., Domachowske J.B. 2001. Eosinophils, eosinophil ribonucleases, and their role in host defense against respiratory virus pathogens. J. Leukoc. Biol. 70, 691-698.
4. Leland P., Raines R. 2001. Cancer chemotherapy: Ribonucleases to the rescue. Chem. Biol. 8, 405-413.
5. Matousek J. 2001. Ribonucleases and their antitumor activity. Comp. Biochem. Physiol. C. Toxicol. Pharmacol. 129, 175-191.
6. Mikulski S.M., Costanzi J.J., Vogelzang N.J., McCachren S., Taub R.N., Chun H., Mittelman A., Panella T., Puccio C., Fine R., Shogen K. 2002. Phase II trial of a single weekly intravenous dose of rapirnase in patient with unresectable malignant mesothelioma. J. Clin. Oncol. 20, 274-281.
7. Ogawa Y., Iwama M., Ohgi K., Tsuji T., Irie M., Itagaki T., Kobajashi H., Inokushi N. 2002. Effect of replacing the aspartic acid/glutamic acid residues of bullfrog sialic acid binding lectin with asparagine/glutamine and arginine on the inhibition of cell proliferation in murine leukemia P388 cells. Biol. Pharm. Bull. 25, 722-727.
8. Antignani A., Naddo M., Cubellis M.V., Russo A., D'Alessio G. 2001. Antitumor action of seminal ribonuclease, its dimeric structure, and its resistance to the ribonuclease inhibitor. Biochemistry. 40, 3492-3496.
9. Newton D.L., Kaur G., Rhim J.S., Sausville E.A., Rybak S.M. 2001. RNA damage and inhibition of neoplastic endothelial cells growth: Effects of human and amphibian ribonucleases. Radiat. Res. 155, 171-174.
10. Maeda T., Mahara K., Kitazoe M., Futami J., Takidini A., Kosaka M., Tada H., Seno M., Yamada H. 2002. RNase 3 (ECP) is an extraordinarily stable protein among human pancreatic-type RNases. J. Biochem. (Tokyo). 132, 737-742.
11. Halicka D.H., Pozarowski P., Ita M., Ardelt W.J., Mikulski S.M., Shogen K., Darzynkiewicz Z. 2002. Enhancement of activation-induced apoptosis of lymphocytes by the cytotoxic ribonuclease (rapirnase). Int. J. Oncol. 21, 1245-1250.
12. Ilinskaya O., Decker K., Koschinski A., Dreyer F., Repp H. 2001. Bacillus intermedius ribonuclease as inhibitor of cell proliferation and membrane current. Toxicology. 156, 101-107.
13. Sevcik J., Urbanikova L., Leland P.A., Raines R.T. 2002. X-Ray structure of two crystalline forms of a streptomycete ribonuclease with cytotoxic activity. J. Biol. Chem. 277, 47325-17330.
14. Olmo N., Turnay J., Gonzalez de Butitrago G., Lopez de Silanes I., Gavilanes J.G., Lizarbe M.A. 2001. Cytotoxic mechanism of the ribotoxin alpha-sarcin. Induction of cell death via apoptosis. Eur. J. Biochem. 268, 2113-2123.
15. Cho S., Joshi J.G. 1989. Ribonuclease inhibitor from pig brain: Purification, characterization, and direct spectrophotometric assay. Anal. Biochem. 176, 175-179.
16. Abraham A.T., Lin J., Newton D.L., Rybak S., Hecht S. 2003. RNA cleavage and inhibition of protein synthesis by bleomycin. Chem. Biol. 10, 45-52.
17. Batey R.T., Doudna J.A. 2002. Structural and energetic analysis of metal ions essential to SRP signal recognition domain assembly. Biochemistry. 41, 11703-11710.
18. McManus M.T. 2003. MicroRNAs and cancer. Semin. Cancer Biol. 13, 253-258.
19. Couzin J. 2002. Small RNAs make big splash. Science. 298, 2296-2297.
20. Saxena S.K., Shogen K., Ardelt W. 2003. Onconase and its therapeutic potential. Lab. Med. 34, 380-387.
21. Saxena S.K., Sirdeshmukh R., Ardelt W., Mikulski S.M., Shogen K., Youle R.J. 2003. Entry into cells and selective degradation of tRNAs by a cytotoxic member of the RNase A family. J. Biol. Chem. 277, 15 142-15146.
22. Ardelt B., Ardelt W., Darzynkiewicz Z. 2003. Cytotoxic ribonucleases and RNA interference (RNAi). Cell Cycle. 2, A10-F12.
23. Sorrentino S., Naddeo M., Russo A., D'Alessio G. 2003. Degradation of double-stranded RNA by human pancreatic ribonuclease: Crucial role of noncatalytic basic amino acid residues. Biochemistry. 42, 10182-19190.
24. Blaszczyk J., Gan J., Tropea J.E., Court D.L., Waugh D.S., Ji X. 2004. Noncatalytic assembly of ribonuclease III with double-stranded RNA. Structure (Cambridge). 12, 457-166.
25. Ran S., Downes A., Thorpe P.E. 2002. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res. 62, 6132-6140.
26. Ran S., Thorpe RE. 2002. Phosphatidylserine is a marker of tumor vasculature and potential target for cancer imaging and therapy. Int. J. Radiat. Oncol. Biol. Phys. 54, 1479-1484.
27. Haigis M.C., Raines R.T. 2002. Secretory ribonucleases are internalized by a dynamin-independent endocytic pathway. J. Cell Sci. 116, 313-324.
28. Bracale A., Spalletti-Cernia D., Mastronicola M., Castaldi R, Mannucci R., Nitsch L., D'Alessio G. 2002. Essential stations in the intracellular pathway of cytotoxic bovine seminal ribonuclease. Biochem. J. 362, 553-560.
29. Gho Y.S., Yoon W.H., Chae C.B. 2002. Antiplasmin activity of a peptide that binds to the receptor-binding site of angiogenin. J. Biol. Chem. 277, 9690-9694.
30. Kourie J.I., Henry C.L. 2002. Ion channel formation and membrane-linked pathologies of misfolded hydrophobic proteins: The role of dangerous unchaperoned molecules. Clin. Exp. Pharmacol. Physiol. 29, 741-753.
31. Egorov S.Yu., Dmitriev I.I., Naumova E.S., Kupriyanova-Ashina F.G. 1996. An immunochemical study of Bacillus intermedius ribonuclease entry into Candida tropicalis cells and effects of the enzyme on yeast growth. Tsitologiya. 38, 66-69.
32. Prior T.I., Kunwar S., Pastan I. 1996. Studies on the activity of barnase toxins in vitro and in vivo. Bioconjug. Chem. 7, 23-29.
33. Mizejewski G.T. 2002. Biological role of alpha-fetoprotein in cancer: Prospects for anticancer therapy. Expert Rev. Anticancer Ther. 2, 709-735.
34. Hursey M., Newton D.L., Hansen H.J., Ruby D., Goldenberg D.M., Rybak S.M. 2002. Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents: A new generation of therapeutics. Leuk. Lymphoma. 43, 953-959.
35. Huhn M., Sasse S., Tur M.K., Matthey B., Scinkothe T., Rybak S.M., Barth S., Engert A. 2001. Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma. Cancer Res. 61, 8737-8742.
36. Di Lorenzo C., Nigro A., Piccoli R., D'Alessio G. 2002. A new RNase-based immunoconjugate selectively cytotoxic for ErbB2-overexpressing cells. FEBS Lett. 516, 208-212.
37. Psarras K., Ueda M., Tanabe M., Kitajima M., Aiso S., Komatsu S., Seno M. 2000. Targeting activated lymphocytes with an antirelay human immunotoxin analogue: Human pancreatic RNase1-human IL-2 fusion. Cytokine. 12, 786-790.
38. Sills R.C., Boorman G.A., Neal J.E., Hong H.L., Devereux T.R. 1999. Mutations in ras genes in experimental tumor of rodents. IARC Sci. Publ. 146, 55-86.
39. Smith M.R., Newton D.L., Mikulski S.M., Rybak S.M. 1999. Cell cycle-related differences in susceptibility of NIH/3T3 cells to ribonucleases. Exp. Cell. Res. 247, 220-232.
40. Ilinskaya O.N., Dreyer F., Mitkevich V.A., Shaw K.L., Pace C.N., Makarov A.A. 2002. Changing the net charge from negative to positive makes ribonuclease Sa cytotoxic. Protein Sci. 11, 2522-2525.
41. Scharovsky O.G., Rozados V.R., Gervasoni S.I., Matar P. 2000. Inhibition of ras oncogene: A novel approach to antineoplastic therapy. J. Biochem. Sci. 7, 292-298.
42. Falconer M., Smith F., Sura-Narwal S., Congrave G., Liu Z., Hayter P., Ciaramella G., Keighley W., Haddock P., Waldron G., Sewing A. 2002. High-throughput screening for ion channel modulators. J. Biomol. Screen. 7, 460-165.
43. Chi X., Sutton E.T., Hellermenn G., Price J.M. 2000. Potassium channel openers prevent beta-amyloid toxicity in bovine vascular endothelial cells. Neurosci. Lett. 290, 9-12.
44. Ca channels Biochem. Biophys. Res. Commun. 314, 550-554.
45. Schmittschmitt J.P., Scholtz M. 2003. The role of protein stability, solubility, and net charge in amyloid fibril formation. Protein Sci. 12, 2374-2378.
46. + current in mouse fibroblasts by lysophosphatidic acid requires a pertussis toxin-sensitive G protein and Ras. Naunyn-Schmiedeberg's Arch. Pharmacol. 358, 509-517.
47. + current by the oncogenic receptor protein tyrosine kinase v-Fms in mouse fibroblasts. Naunyn-Schmiedeberg's Arch. Pharmacol. 357, 378-384.
48. Ilinskaya O.N., Kolpakov A.I. Cell targets for the antitumor action of microbial endonucleases. Naukoemk. Tekhnol. 4, 61-67.
49. + channel of intermediate conductance: A possible target for immune suppression. Expert. Opin. Ther. Targets. 6, 623-636.
50. Ilinskaya O.N., Ivanchenko O.B., Karamova N.S., Kipenskaya L.V. 1996. SOS-inducing ability of native and mutant microbial ribonucleases. Mut. Res. 354, 203-209.
51. Ilinskaya O.N., Ivanchenko O.B., Karamova N.S. 1995. Bacterial ribonuclease: Mutagenic effect in microbial test-systems. Mutagenesis. 10, 165-170.
52. Ilinskaya O.N., Vamvakas S. 1997. Nephrotoxic effects of bacterial ribonucleases in the isolated perfused rat kidney. Toxicology. 120, 55-63.
53. Ilinskaya O.N., Frai H. 2000. Genotoxic effects of ribonuclease in vivo. Biopolim. Kletka. 4, 270-274.
54. Iordanov M.S., Ryabinina O.P., Wong J., Newton D.L., Rybak S.M., Magun B.E. 2000. Molecular determinants of apoptosis induced by the cytotoxic ribonuclease onconase: Evidence for cytotoxic mechanisms different from inhibition of protein synthesis. Cancer Res. 60, 1983-1994.
55. Futami J., Maeda T., Kitazoe M., Nukui E., Tada H., Seno M., Kosaka M., Yamada H. 2001. Preparation of potent cytotoxic ribonucleases by cationization: Enhanced cellular uptake and decreased interaction with ribonuclease inhibitor by chemical modification of carboxyl groups. Biochemistry. 40, 7518-7524.
56. Rosenberg H.F. 1995. Recombinant human eosinophil cationic protein. Ribonuclease activity is not essential for cytotoxicity. J. Biol. Chem. 270, 7876-7881.
57. Kurinenko B.M., Bulgakova R.Sh., Davydov R.E. 1998. Effect of ribonuclease from Bacillus intermedius on human blood lymphocytes. FEMS Immunol. Med. Microbiol. 21, 117-122.
58. Klink T.A., Raines R.T. 2000. Conformational stability is a determinant of ribonuclease A cytotoxicity. J. Biol Chem. 275, 17463-17467.
59. Leland P.A., Staniszewski K.E., Kim B.M., Raines R. 2000. A synamorphic disulfide bond is critical for the conformational stability and cytotoxicity of an amphibian ribonuclease. FEBS Lett. 477, 203-207.
60. Notomista E., Catanzano F., Graziano G., Di Gaetano S., Barone G., Di Donate A. 2001. Contribution of chain termini to the conformational stability and biological activity of onconase. Biochemistry. 40, 9097-9103.
61. Matousek J., Pouckova P., Hlouskova D., Zadvinova M., Soucek J., Skvor J. 2004. Effect of hyaluronidase and PEG chain conjugation on the biologic and antitumor activity of RNase A. J. Contr. Release. 94, 401-410.
62. Kim B.M., Kim H., Raines R., Lee Y. 2004. Glycosylation of onconase increases its conformational stability and toxicity for cancer cells. Biochem. Biophys. Res. Commun. 315, 976-983.
63. Piccoli R., Di Gaetano S., De Lorenzo C., Grauso M., Monaco C., Spalletti-Cernia D., Laccetti P., Cinatl J., Matousek J., D'Alessio G. 1999. A dimeric mutant of human pancreatic ribonuclease with selective cytotoxicity toward malignant cells. Proc. Natl. Acad. Sci. USA. 96, 7768-7773.
64. Spalletti-Cernia D., Sorrentino R., Di Gaetano S., Piccoli R., Santoro V., D'Alessio G., Laccetti P., Vacchio G. 2004. Highly selective toxic and proapoptotic effects of two dimeric ribonucleases on thyroid cancer cells compared to the effects of doxorubicin. Br. J. Cancer. Res. 90, 270-277.
65. Matousek J., Gotte G., Pouckova P., Soucek J., Slavik T., Vottariello F., Libonati M. 2003. Antitumor activity and other biological actions of oligomers of ribonuclease A. J. Biol. Chem. 278, 23817-23822.
66. Futami J., Nukui E., Maeda T., Kosaka M., Tada H., Sano M., Yamada H. 2002. Optimum modification for the highest cytotoxicity of cationized ribonuclease. J. Biochem. (Tokyo). 132, 223-228.
67. Makarov A.A., Ilinskaya O.N. 2003. Cytotoxic ribonucleases: Molecular weapons and their targets. FEBS Lett. 540, 15-20.
68. Bosch M., Benito A., Ribo M., Puig T., Beaumelle B., Vilanova M. 2004. A nuclear localization sequence endows human pancreatic ribonuclease with cytotoxic activity. Biochemistry. 43, 2167-2177.
69. Iwama M., Ogawa Y., Sasaki N., Nitta K., Takajanagi Y., Ohgi K., Tsuji T., Irie M. 2001. Effect of modification of the carboxyl groups of sialic acid binding lectin from bullfrog (Rana catesbiana) oocyte on anti-tumor activity. Biol. Pharm. Bull. 24, 978-981.
70. Xu H., He W.J., Liu W.Y. 2004. A novel ribotoxin with ribonuclease activity that specifically cleaves a single phosphodiester bond in rat 28S ribosomal RNA and inactivates ribosome. Arch. Biochem. Biophys. 427, 30-40.
71. Xia H.C., Li F., Zhang Z.C. 2003. Purification and characterization of Moschatin, a novel type I ribosome-inactivated protein from the mature seeds of pumpkin (Cucurbita moschata), and preparation of its immunotoxin against human melanoma cells. Cell Res. 13, 369-374.
72. Masaki H., Ogawa T. 2002. The modes of action of colicins E5 and D, and related cytotoxic tRNases. Biochimie. 84, 433-138.
73. Gaur D., Seth D., Batra J.K. 2002. Glycine 38 is crucial for the ribonucleolytic activity of human pancreatic ribonuclease on double-stranded RNA. Biochem. Biophys. Res. Commun. 297, 390-395.
74. Juan G., Ardelt B., Li X., Mikulski S.M., Shogen K., Ardelt W., Mittelman A., Darzynkiewicz Z. 1998. G1 arrest of U-937 cells by onconase is associated with suppression of cyclin D3 expression, induction of p16INK4A, p21WAF1/CIP1 and p27KIP and decreased pRb phosphorylation. Leukemia. 12, 1241-1248.
75. Vlasov V.V. 2004. Oligonucleotides as a basis for gene-directed therapeutics. Vestn. Ross. Akad. Nauk. 74, 419-423.
76. Kuwabara T., Hsieh J., Nakashima K., Taira K., Gage F.H. 2004. A small modulatory dsRNA specifies the fate of adult neural stem cells. Cell. 116, 779-793.